Article
Oncology
Sotirios P. Fortis, Panagiota Batsaki, Savvas Stokidis, Dimitra Moschandreou, Elisavet Grouzi, Constantin N. Baxevanis, Angelos D. Gritzapis, Maria Goulielmaki
Summary: The discovery of prognostic biomarkers is important for personalized treatment and precision oncology. In this study, a prognostic signature consisting of eight genes was identified in peripheral blood samples of prostate cancer patients, which can be easily accessed and have significant prognostic value for various types of cancer.
Article
Biochemistry & Molecular Biology
Ying Z. Mazzu, Yu-Rou Liao, Subhiksha Nandakumar, Lina E. Jehane, Richard P. Koche, Sai Harisha Rajanala, Ruifang Li, HuiYong Zhao, Travis A. Gerke, Goutam Chakraborty, Gwo-Shu Mary Lee, Gouri J. Nanjangud, Anuradha Gopalan, Yu Chen, Philip W. Kantoff
Summary: Amplification or overexpression of CSN5 is associated with poor prognosis in prostate cancer, impacting various cellular functions involved in tumor development. Inhibiting CSN5 can suppress prostate cancer progression through multiple pathways.
Article
Oncology
Wei Li, Runze Zhou, Bo Sun, Xin Jin, Yuan Chen, Xuefen Xu
Summary: The study indicates that low AP004608.1 expression is associated with favorable survival outcomes in prostate cancer patients, suggesting its potential as a prognostic biomarker with important clinical implications.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Zhuo Huang, Ying Tang, Yuyan Wei, Jingyu Qian, Yifan Kang, Duohao Wang, Miao Xu, Ling Nie, Xueqin Chen, Ni Chen, Qiao Zhou
Summary: Neuroendocrine differentiation (NED) characterized by the expression of neuroendocrine markers, such as chromogranin A (CgA), is frequently observed in advanced prostate cancer (PCa), the prognostic significance of which is still controversial. The study found that CgA expression was an independent adverse prognostic factor for both metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC).
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biology
Sofia Lage-Vickers, Juan Bizzotto, Maria Pia Valacco, Pablo Sanchis, Sergio Nemirovsky, Estefania Labanca, Carlos Scorticati, Osvaldo Mazza, Antonina Mitrofanova, Nora Navone, Elba Vazquez, Javier Cotignola, Geraldine Gueron
Summary: This study identifies high YWHAZ and NDRG1 expression as molecular biomarkers associated with poor prognosis in prostate cancer patients, defining two subgroups with high and intermediate risk of disease progression. YWHAZ outperforms Gleason score in predicting aggressiveness of prostate cancer beyond 60 months post-diagnosis.
COMMUNICATIONS BIOLOGY
(2021)
Article
Health Care Sciences & Services
Gianluca Ingrosso, Emanuele Ali, Simona Marani, Simonetta Saldi, Rita Bellavita, Cynthia Aristei
Summary: This article reviewed the literature of the past 10 years and provided an overview of commercially available tissue-based biomarkers, specifically mRNA-based gene expression classifiers. Despite the published data, the systematic use of these tests in prostate cancer is currently not recommended due to insufficient evidence.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Savvas Stokidis, Constantin N. Baxevanis, Sotirios P. Fortis
Summary: This study confirms the prognostic value of HLA-A*02:01 and HLA-A*24:02 in prostate cancer (PCa), demonstrating that these alleles can serve as valuable prognostic biomarkers for guiding treatment decisions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Jie Mei, Yan Liu, Xinqian Yu, Leiyu Hao, Tao Ma, Qiang Zhan, Yan Zhang, Yichao Zhu
Summary: DAAM1 and YWHAZ are significantly upregulated in BrCa tissues and associated with poor prognosis. YWHAZ interacts with and colocalizes with DAAM1 in BrCa cells, playing a crucial role in microfilament remodeling and RhoA activation. Moreover, miR-613 directly targets both YWHAZ and DAAM1, leading to inhibition of BrCa cell migration by blocking the YWHAZ-DAAM1 complex.
CELL DEATH DISCOVERY
(2021)
Review
Oncology
Yuequn Niu, Sarah Foerster, Michael Muders
Summary: Perineural invasion (PNI) is a common indicator of tumor metastasis in various malignancies, including prostate cancer. PNI involves the interaction between tumor cells and nerve components in the tumor microenvironment, creating a perineural niche that supports tumor cell survival and invasion, benefiting nerve cells. The molecular mechanisms of PNI are still limitedly understood. Clinically, PNI is associated with adverse clinicopathological parameters and poor outcomes for prostate cancer patients. However, there is controversy over whether PNI can act as an independent prognostic predictor due to inconsistent research aims, sample types, statistical methods, and the definition and inclusion criteria. This review summarizes and compares the prognostic significance of PNI in prostate cancer based on existing literature and suggests that a more standardized description of PNI would enhance the understanding of its clinical relevance.
Article
Oncology
Albert Carrion, Mercedes Ingelmo-Torres, Juan Jose Lozano, Ruth Montalbo, Maurizio D'Anna, Claudia Mercader, Elena Velez, Maria Jose Ribal, Antonio Alcaraz, Lourdes Mengual
Summary: The study identified the expression of ASF1B and MCL1 genes, Gleason score, extracapsular extension, seminal vesicle invasion, and positive margins as independent prognostic factors of biochemical recurrence in clinically localized prostate cancer patients. The risk score developed using these variables could effectively discriminate between different groups of patients with significantly different probabilities of biochemical recurrence.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Editorial Material
Medicine, General & Internal
Oliver Sartor
Summary: Between 1999 and 2009, a total of 82,429 men aged 50-69 in the UK underwent PSA testing as part of the ProtecT trial. After a median follow-up of 15 years, the results of this massive undertaking can now be reviewed.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Genetics & Heredity
Ruisong Wang, Ziyi Qin, Huiling Luo, Meisen Pan, Mingyao Liu, Pinhong Yang, Tieliu Shi
Summary: In this study, the prognostic and diagnostic values of the PNN gene in prostate cancer were analyzed using the TCGA-PCa dataset and GEO validation. The results showed that PNN may serve as an independent prognostic factor and potential biomarker for prostate cancer. The study also revealed the involvement of PNN in RNA splicing and spliceosomes, and a prognostic signature based on methylation status was constructed.
FRONTIERS IN GENETICS
(2022)
Article
Endocrinology & Metabolism
Tsuyoshi Matsuda, Yasuyoshi Miyata, Yuichiro Nakamura, Asato Otsubo, Yuta Mukae, Junki Harada, Kensuke Mitsunari, Tomohiro Matsuo, Kojiro Ohba, Bungo Furusato, Hideki Sakai
Summary: LATS2 acts as a tumor suppressor in prostate cancer, and its expression is correlated with clinicopathological features, proliferation index, and biochemical recurrence in patients with PC.
Article
Oncology
Zhengcun Wu, Chengxing Xia, Chao Zhang, Delin Yang, Kaili Ma
Summary: This study investigates the role of SNCA gene in bladder cancer (BLCA) and its potential as a prognostic diagnostic biomarker. The results show that SNCA is downregulated in BLCA tumor tissues and is negatively correlated with DNA methylation. High SNCA expression is associated with poor overall survival. SNCA is also found to play a role in immune cell infiltration, particularly with T cells. Therefore, SNCA may serve as a promising prognostic biomarker in BLCA patients.
Article
Multidisciplinary Sciences
Orlandric Miree, Sanjeev Kumar Srivastava, Mohammad Aslam Khan, Fnu Sameeta, Srijan Acharya, Harrison Ndetan, Karan Pal Singh, Kate Louise Hertweck, Santanu Dasgupta, Luciana Madeira da Silva, Rodney Paul Rocconi, James Elliot Carter, Seema Singh, Ajay Pratap Singh
Summary: The study found that aberrant MYB expression in ovarian cancer is positively correlated with tumor grades and stages, and has race-specific prognostic value for African American patients, but not for Caucasian American patients. High levels of MYB transcripts in epithelial ovarian cancer subtypes are associated with poor survival in African American patients, highlighting MYB as a potentially useful clinical biomarker for prognosis in this population.
SCIENTIFIC REPORTS
(2021)